Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지

The Current Status of Adenovirus-based Cancer Gene Therapy

  • Shirakawa, Toshiro (International Center for Medical Research and Treatment (ICMRT), Kobe University School of Medicine)
  • Received : 2008.05.02
  • Accepted : 2008.05.04
  • Published : 2008.06.30
⟨ Previous Next ⟩

Abstract

Adenoviruses are the most commonly used gene-delivery vectors due to the efficiency of their in vivo gene transfer. Since 1993, about 300 protocols using an adenoviral vector have been performed, although they have yet to be proven effective in clinical trials. The adenovirus-based vector has been continuously improved by modification of the adenoviral genome and capsid, and novel adenovirus-delivery systems, such as the carrier-cell delivery system, have been recently proposed. Adenovirus-based cancer gene therapy is fast becoming one component of a multi-modality treatment approach to advanced cancer, along with surgery, radiotherapy, and chemotherapy.

Keywords

References

  1. Biederer, C., Ries, S., Brandts, C.H., and Mccormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163-175 https://doi.org/10.1007/s00109-001-0295-1
  2. Clayman, G.L., El-naggar, A.K., Lippman, S.M., Henderson, Y.C., Frederick, M., Merritt, J.A., Zumstein, L.A., Timmons, T.M., Liu, T.J., Ginsberg, L., et al. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232 https://doi.org/10.1200/JCO.1998.16.6.2221
  3. Crystal, R.G., Mcelvaney, N.G., Rosenfeld, M.A., Chu, C.S., Mastrngeli, A., Hay, J.G., Brody, S.L., Jaffe, H.A., Eissa, N.T., and Danel, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51 https://doi.org/10.1038/ng0994-42
  4. Fallaux, F.J., Bout, A., Van der Velde, I., Van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., Van Ormondt, H., Van der EB, A.J., et al. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-com-petent adenoviruses. Hum. Gene Ther. 9, 1909-1917 https://doi.org/10.1089/hum.1998.9.13-1909
  5. Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D.G., Peabody, J., Deperalta-Venturian, M., Xia, X., Brown, S., Lu, M., et al. (2003). Phase I study of replication-competent adenovirus- mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506
  6. Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G.I., Soutar, D.S., Otto, R., Robertson, A.G., Park, O., Gulley, M.L., Heise, C., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806
  7. Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74 https://doi.org/10.1099/0022-1317-36-1-59
  8. Hamada, K., Desaki, J., Nakagawa, K., Zhang, T., Shirakawa, T., Gotoh, A., and Tagawa, M. (2007). Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol. Ther. 15, 1121-1128 https://doi.org/10.1038/sj.mt.6300128
  9. Huebner, R.J., Rowe, W.P., Schatten, W.E., Smith, R.R., and Thomas, L.B. (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218 https://doi.org/10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7
  10. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16, 16-29 https://doi.org/10.1038/sj.mt.6300321
  11. Lonberg-Holm, K., and Philipson, L. (1969). Early events of virus-cell interaction in an adenovirus system. J. Virol. 4, 323-338
  12. Mettler, N.E., Clarke, D.H., and Casals, J. (1982). Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression. Infect. Immun. 37, 23-27
  13. Mizuguchi, H., and Hayakawa, T. (2004). Targeted adenovirus vectors. Hum. Gene Ther. 15, 1034-1044 https://doi.org/10.1089/hum.2004.15.1034
  14. Nemunaitis, J., Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D.D., Kemp, B.L., et al. (2000). Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18, 609-622 https://doi.org/10.1200/JCO.2000.18.3.609
  15. Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016-1027 https://doi.org/10.1089/hum.2005.16.1016
  16. Power, A.T., and Bell, J.C. (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. 15, 660-665 https://doi.org/10.1038/sj.mt.6300098
  17. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158 https://doi.org/10.1016/j.ymgme.2003.08.016
  18. Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H., and Ward, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570-573
  19. Russell, W.C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81, 2573-2604 https://doi.org/10.1099/0022-1317-81-11-2573
  20. Sakhuja, K., Reddy, P.S., Ganesh, S., Cantaniag, F., Pattison, S., Limbach, P., Kayda, D.B., Kadan, M.J., Kaleko, M., and Connelly, S. (2003). Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. 14, 243-254 https://doi.org/10.1089/10430340360535797
  21. Saukkonen, K., and Hemminki, A. (2004). Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4, 683-696 https://doi.org/10.1517/14712598.4.5.683
  22. Shirakawa, T., Terao, S., Hinata, N., Tanaka, K., Takenaka, A., Hara, I., Sugimura, K., Matsuo, M., Hamada, K., Fuji, K., et al. (2007). Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum. Gene Ther. 18, 1225-1232 https://doi.org/10.1089/hum.2007.074
  23. Southam, C.M., and Moore, A.E. (1952). Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5, 1025-1034 https://doi.org/10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q
  24. Southam, C.M., Hilleman, M.R., and Werner, J.H. (1956). Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. J. Lab Clin. Med. 47, 573-582
  25. Vaha-Koskela, M.J., Heikkila, J.E., and Hinkkanen, A.E. (2007). Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178-216 https://doi.org/10.1016/j.canlet.2007.02.002
  26. Vattemi, E., and Claudio, P.P. (2006). Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 19, 329-337 https://doi.org/10.1358/dnp.2006.19.6.1015352
  27. Volpers, C., and Kochanek, S. (2004). Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6 (Suppl. 1), S164-171 https://doi.org/10.1002/jgm.496
  28. Yu, W., and Fang, H. (2007). Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141-148 https://doi.org/10.2174/156800907780058817
  29. Zeimet, A.G., and Marth, C. (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415-422 https://doi.org/10.1016/S1470-2045(03)01139-2